Aglazin Anagrelid Anagrelide sulfate AN-100瑞博西尼,

Ribociclib

Another Name
Aglazin Anagrelid Anagrelide sulfate AN-100瑞博西尼,
Indications
hormone receptor-positive (HR+)
Reg No
09 L 1191/24
Inspection No
2131-24
dosage form:Pills
Specs:200mg*21 Pills
Indate:24 months
Date：2024-10-18 Views：1214
Drug Info

COMPOSITION:

Each LuciRibo tablet contains Ribociclib succinate 254.40 mg equivalent to Ribociclib………200mg

INDICATION:

LuciRibo is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:

  • An aromatase inhibitor as initial endocrine-based therapy; or
  • Fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men.

DOSAGE AND USE:

LuciRibo tablets are taken orally with or without food in combination with an aromatase inhibitor or Fulvestrant.

• Recommended starting dose: 600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment.

• Dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability.

Tablets should be swallowed whole & not chewed or crushed.

STORAGE:

In a dry place and store at 20℃ to 25℃.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciRibo during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/ribociclib/

Related News